Mustafa Tosur1, Susan M Geyer2, Henry Rodriguez3, Ingrid Libman4, David A Baidal5, Maria J Redondo6. 1. Section of Diabetes and Endocrinology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, 6701 Fannin St, Suite 10.20, Houston, TX, 77030, USA. mustafa.tosur@bcm.edu. 2. Health Informatics Institute, Department of Pediatrics, University of South Florida, Tampa, FL, USA. 3. University of South Florida Diabetes Center, Department of Pediatrics, University of South Florida, Tampa, FL, USA. 4. Division of Pediatric Endocrinology, Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 5. Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami, Miami, FL, USA. 6. Section of Diabetes and Endocrinology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, 6701 Fannin St, Suite 10.20, Houston, TX, 77030, USA.
Abstract
AIMS/HYPOTHESIS: We hypothesised that progression of islet autoimmunity and type 1 diabetes mellitus differs among races/ethnicities in at-risk individuals. METHODS: In this study, we analysed the data from the Type 1 Diabetes TrialNet Pathway to Prevention Study. We studied 4873 non-diabetic, autoantibody-positive relatives of individuals with type 1 diabetes followed prospectively (11% Hispanic, 80.9% non-Hispanic white [NHW], 2.9% non-Hispanic black [NHB] and 5.2% non-Hispanic other [NHO]). Primary outcomes were time from single autoantibody positivity confirmation to multiple autoantibody positivity, and time from multiple autoantibody positivity to type 1 diabetes mellitus diagnosis. RESULTS: Conversion from single to multiple autoantibody positivity was less common in Hispanic individuals than in NHW individuals (HR 0.66 [95% CI 0.46, 0.96], p = 0.028) adjusting for autoantibody type, age, sex, Diabetes Prevention Trial Type 1 Risk Score and HLA-DR3-DQ2/DR4-DQ8 genotype. In participants who screened positive for multiple autoantibodies (n = 2834), time to type 1 diabetes did not differ by race/ethnicity overall (p = 0.91). In children who were <12 years old when multiple autoantibody positivity was determined, being overweight/obese had differential effects by ethnicity: type 1 diabetes risk was increased by 36% in NHW children (HR 1.36 [95% CI 1.04, 1.77], p = 0.024) and was nearly quadrupled in Hispanic children (HR 3.8 [95% CI 1.6, 9.1], p = 0.0026). We did not observe this interaction in participants who were ≥12 years old at determination of autoantibody positivity, although this group size was limited. No significant differential risks were observed between individuals of NHB and NHW ethnicity. CONCLUSIONS/ INTERPRETATION: The risk and rate of progression of islet autoimmunity were lower in Hispanic compared with NHW at-risk individuals, while significant differences in the development of type 1 diabetes were limited to children <12 years old and were modified by BMI.
AIMS/HYPOTHESIS: We hypothesised that progression of islet autoimmunity and type 1 diabetes mellitus differs among races/ethnicities in at-risk individuals. METHODS: In this study, we analysed the data from the Type 1 Diabetes TrialNet Pathway to Prevention Study. We studied 4873 non-diabetic, autoantibody-positive relatives of individuals with type 1 diabetes followed prospectively (11% Hispanic, 80.9% non-Hispanic white [NHW], 2.9% non-Hispanic black [NHB] and 5.2% non-Hispanic other [NHO]). Primary outcomes were time from single autoantibody positivity confirmation to multiple autoantibody positivity, and time from multiple autoantibody positivity to type 1 diabetes mellitus diagnosis. RESULTS: Conversion from single to multiple autoantibody positivity was less common in Hispanic individuals than in NHW individuals (HR 0.66 [95% CI 0.46, 0.96], p = 0.028) adjusting for autoantibody type, age, sex, Diabetes Prevention Trial Type 1 Risk Score and HLA-DR3-DQ2/DR4-DQ8 genotype. In participants who screened positive for multiple autoantibodies (n = 2834), time to type 1 diabetes did not differ by race/ethnicity overall (p = 0.91). In children who were <12 years old when multiple autoantibody positivity was determined, being overweight/obese had differential effects by ethnicity: type 1 diabetes risk was increased by 36% in NHW children (HR 1.36 [95% CI 1.04, 1.77], p = 0.024) and was nearly quadrupled in Hispanic children (HR 3.8 [95% CI 1.6, 9.1], p = 0.0026). We did not observe this interaction in participants who were ≥12 years old at determination of autoantibody positivity, although this group size was limited. No significant differential risks were observed between individuals of NHB and NHW ethnicity. CONCLUSIONS/ INTERPRETATION: The risk and rate of progression of islet autoimmunity were lower in Hispanic compared with NHW at-risk individuals, while significant differences in the development of type 1 diabetes were limited to children <12 years old and were modified by BMI.
Entities:
Keywords:
Diabetes in childhood; Genetics of type 1 diabetes; Prediction and prevention of type 1 diabetes; Weight regulation and obesity
Authors: Elizabeth J Mayer-Davis; Jean M Lawrence; Dana Dabelea; Jasmin Divers; Scott Isom; Lawrence Dolan; Giuseppina Imperatore; Barbara Linder; Santica Marcovina; David J Pettitt; Catherine Pihoker; Sharon Saydah; Lynne Wagenknecht Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler Journal: Pediatr Diabetes Date: 2008-09-24 Impact factor: 4.866
Authors: Maria Jose Redondo; Ingrid Libman; Peiyao Cheng; Craig Kollman; Mustafa Tosur; Robin L Gal; Fida Bacha; Georgeanna J Klingensmith; Mark Clements Journal: Diabetes Care Date: 2018-03-01 Impact factor: 19.112
Authors: Andrea K Steck; Ping Xu; Susan Geyer; Maria J Redondo; Peter Antinozzi; John M Wentworth; Jay Sosenko; Suna Onengut-Gumuscu; Wei-Min Chen; Stephen S Rich; Alberto Pugliese Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: Manuela Battaglia; Simi Ahmed; Mark S Anderson; Mark A Atkinson; Dorothy Becker; Polly J Bingley; Emanuele Bosi; Todd M Brusko; Linda A DiMeglio; Carmella Evans-Molina; Stephen E Gitelman; Carla J Greenbaum; Peter A Gottlieb; Kevan C Herold; Martin J Hessner; Mikael Knip; Laura Jacobsen; Jeffrey P Krischer; S Alice Long; Markus Lundgren; Eoin F McKinney; Noel G Morgan; Richard A Oram; Tomi Pastinen; Michael C Peters; Alessandra Petrelli; Xiaoning Qian; Maria J Redondo; Bart O Roep; Desmond Schatz; David Skibinski; Mark Peakman Journal: Diabetes Care Date: 2019-11-21 Impact factor: 19.112
Authors: Mustafa Tosur; Mario A Cleves; Jay M Sosenko; Ingrid Libman; David A Baidal; Ashok Balasubramanyam; Maria J Redondo Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958